All In Biotech

Drug Trial Radar · NCT06984588

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

A Phase II/III, Randomized, Multicenter, Open-Label Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Mar 28, 2024

Primary completion

Aug 5, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
TJ Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II/III, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with toripalimab, toripalimab monotherapy, and pembrolizumab monotherapy in patients with previously untreated locally advanced unresectable or metastatic PD-L1-positive (tumor proportion score \[TPS\] ≥ 1%) and CD73-positive (TC/IC \> 30%; TC/IC defined as the higher of either the proportion of CD73-positive tumor cells or the proportion of CD73-positive immune cells at any intensity \[IHC1+ or above\]) NSCLC who are not suitable for targeted therapies such as EGFR, ALK, etc. The number of enrolled subjects with PD-L1 TPS ≥ 50% will be limited to approximately 60% of the total sample size to reflect the natural prevalence of advanced NSCLC. Patients who have received adjuvant or neoadjuvant therapy other than immune checkpoint inhibitor treatments are allowed to participate in this study, provided that such treatments have been completed at least 12 months prior to the occurrence of recurrence or metastasis. During the screening period, tumor samples will be collected in advance and tested by the central laboratory for PD-L1 expression levels using the PD-L1 IHC 22C3 pharmDx assay and CD73 expression levels using the CD73 antibody assay (immunohistochemistry). Previous PD-L1 testing results obtained using the PD-L1 IHC 22C3 pharmDx assay will be accepted. Patients with PD-L1 positive expression (TPS ≥ 1%) and high CD73 expression (TC/IC \> 30%) will meet the inclusion criteria. Patients who do not meet the eligibility criteria as judged by the investigator may be re-screened once. Patients with non-squamous NSCLC will be required to confirm the absence of EGFR-sensitive mutations or ALK fusion; patients with unknown EGFR and ALK expression status will be required to undergo testing and provide clinical laboratory test results prior to study enrollment, and may be enrolled after relevant driver gene mutations are ruled out. Meanwhile, patients with other definite actionable driver gene alterations (such as: ROS1 fusions, RET fusions, NTRK1/2/3 fusions, BRAF V600E mutations, MET14 exon skipping mutations, etc.) will be excluded from this study. Controversial cases with actionable gene mutations will be submitted to the study expert panel for joint decision. This study includes Phase II and Phase III stages. Approximately 150 subjects will be enrolled in the Phase II stage. Based on the evaluation of the efficacy, safety, PK, and PD results of the Phase II study, a decision will be made on whether to proceed to the Phase III study. Approximately 300 subjects will be enrolled in the Phase III stage.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • UliledlimabDrug

    30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,

  • ToripalimabDrug

    240 mg on Day 1, once every 3 weeks (Q3W)

  • PembrolizumabDrug

    200 mg on Day 1, once every 3 weeks (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From the date of randomization to the date of first documented disease progression (assessed by a blinded independent central review [BICR] according to RECIST v1.1) or death from any cause, whichever occurs first,assessed up to 6 months

Locations

64 sites in 1 country. Site status is shown where the registry gives one.

  • Anyang Tumour Hospital

    Anyang, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, China

  • Bejing Chao-Yang Hospital, Capital Medical University

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China

  • Binzhou Medical University Hospital

    Binzhou, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Xiangya Hospital of Central South University

    Changsha, China

  • Army characteristic Hospital Center( Daping Hospital of the Third Military Medical University)

    Chongqing, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • Chongqing University Three Gorges Hospital

    Chongqing, China

  • The People's Hospital of Dongguan

    Dongguan, China

  • The first people's hospital of Foshan

    Foshan, China

  • First Affiliated Hospital of Gannan Meidcal University

    Ganzhou, China

  • Ganzhou People's Hospital

    Ganzhou, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Guizhou Provincial People's Hospital

    Guiyang, China

  • Harbin Medical university cancer hospital

    Ha’erbin, China

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, China

  • Anhui provincial cancer hospital

    Hefei, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China

  • Jiamusi Tumour Hospital

    Jiamusi, China

  • Jiangmen Central hospital

    Jiangmen, China

  • Jinan Central Hospital

    Jinan, China

  • Affiliated Hospital of Jining Medical University

    Jining, China

  • Linyi People's Hospital

    Linyi, China

  • Lishui Central Hospital

    Lishui, China

  • Liuzhou Central Hospital

    Liuzhou, China

  • Longyan First Hospital

    Longyan, China

  • Jiangxi Cancer Hospital

    Nanchang, China

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, China

  • Nanchong Central Hospital

    Nanchong, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Guangxi Medical University Cancer Hospital

    Nanning, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • Nantong Tumor Hospital

    Nantong, China

  • Nanyang Cenreal Hospital

    Nanyang, China

  • The Second People's Hospital of Neijiang

    Neijiang, China

  • Qingdao Central Hospital

    Qingdao, China

  • The First People's Hospital Of Qujing

    Qujing, China

  • Yuebei People's Hospital

    Shaoguan, China

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.